Alto Neuroscience (ANRO) Common Equity (2023 - 2026)

Alto Neuroscience (ANRO) has 4 years of Common Equity data on file, last reported at $3000.0 in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 100.0% year-over-year to $3000.0; the trailing twelve-month figure through Mar 2026 stood at $3000.0 (down 100.0% YoY), and the FY2025 full-year result was $151.1 million, changed 0.21% from the prior year.
• Common Equity eased to $3000.0 in Q1 2026, from $151.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $193.1 million in Q1 2024 to a low of -$71.7 million in Q4 2023.
• A 4-year average of $67.1 million and a median of $123.4 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity jumped 526.99% in 2024 and tumbled 100.0% in 2025, its largest moves.
• Tracing ANRO's Common Equity over 4 years: stood at -$71.7 million in 2023, then surged by 311.32% to $151.5 million in 2024, then decreased by 0.21% to $151.1 million in 2025, then slumped by 100.0% to $3000.0 in 2026.
• Business Quant data shows ANRO's Common Equity at $3000.0 in Q1 2026, $151.1 million in Q4 2025, and $3000.0 in Q3 2025.